Method of treating proliferative disorders and other pathological conditions mediated by Bcr-Abl, c-Kit, DDR1, DDR2 or PDGF-R kinase activity

Details for Australian Patent Application No. 2010322102 (hide)

Owner Novartis AG

Inventors Gallagher, Neil; Yin, Ophelia

Agent Davies Collison Cave

Pub. Number AU-A-2010322102

PCT Pub. Number WO2011/062927

Priority 61/261,812 17.11.09 US

Filing date 17 November 2010

Wipo publication date 26 May 2011

International Classifications

A61K 31/506 (2006.01) - not condensed and containing further heterocyclic rings

A61K 9/00 (2006.01) Medicinal preparations characterised by special physical form

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

24 May 2012 PCT application entered the National Phase

  PCT publication WO2011/062927 Priority application(s): WO2011/062927

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2010322105-Combination

2010322100-Down-the-hole drill hammer having a reverse exhaust system and segmented chuck assembly